Table 1.
Baseline characteristics and clinical details of patient cohort
| Patient baseline and clinical characteristics | Number (%) | Median | Iinterquartile range | Range |
|---|---|---|---|---|
| Age (years) | 3 | 1–7 | 0.04–15.00 | |
| Sex | ||||
| Female | 26 (53) | |||
| Male | 23 (47) | |||
| Height (cm) | 95.0 | 74.0–120.0 | 44.0–173.0 | |
| Weight (kg) | 12.9 | 8.0–28.5 | 1.9–70.0 | |
| Ethnicity | 43 available | |||
| White British | 25 (58.1) | |||
| Other White | 6 (14.0) | |||
| Pakistani | 9 (20.9) | |||
| Other Asian background | 3 (7.0) | |||
| Diagnosis at admission | ||||
| Pneumonia | 12 (24.5) | |||
| SIRS/sepsis/shock | 12 (24.5) | |||
| Cardiac arrest | 5 (10.2) | |||
| Elective surgical | 4 (8.2) | |||
| Emergency Surgical | 4 (8.2) | |||
| Trauma | 3 (6.1) | |||
| Seizures | 2 (4.1) | |||
| Other | 7 (14.3) | |||
| Pre-existing illness | ||||
| None | 16 (32.6) | |||
| Neuromuscular | 2 (4.1) | |||
| Genetic | 7 ( 14.3) | |||
| Seizures | 3 ( 6.1) | |||
| Other | 21 (42.8) | |||
| Ventilated (days) | 43 (87.7) | 5 | 3–9 | 2–14 |
| Death | 5 (10.2) | |||
| CVVH | 1 (2) | |||
| Inotrope score | 44 | |||
| Highest | 0 | 0–9 | 0–61 | |
| Lowest | 0 | 0–0 | 0–13 | |
| PELOD score | 44 | |||
| Highest | 13 | 11–21 | 0–41 | |
| Lowest | 1 | 0–11 | 0–20 | |
| Blood products | ||||
| Whole blood | 18 (37.5) | |||
| Fresh frozen plasma | 11 (22.9) | |||
| Cryoprecipitate | 1 (2.0) | |||
| Platelets | 3 (6.3) | |||
| Urine output (mL/kg/h) | ||||
| Highest | 7.1 | 5.4–11.1 | 0.9–15.3 | |
| Lowest | 0.5 | 0.4–0.7 | 0.0–1.4 | |
| Nephrotoxic medication | 33 (67.3) | |||
| Aminoglycosides | 9 (18.4) | |||
| Vancomycin | 1 (2.0) | |||
| Teicoplanin | 4 (8.2) | |||
| Furosemide | 24 (49.0) | |||
| Nonsteroidal anti-inflammatory drugs | 8 (16.3) | |||
CVVH, Continuous veno-venous hemofiltration, PELOD, Paediatric Logistic Organ Dysfunction